Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated and audited annual results for 2016.
The company has reported €28.9 million profit which is decrease comparing last year published profit of €39.9 million.
The company said that the Board of Directors will propose a dividend of €0.85 per share, up 30%, to the shareholders at the General Meeting on May 19, 2017.